The clonal evolution of leukemic stem cells in T-cell acute lymphoblastic leukemia

Current Opinion in Hematology

Volumn 21, Issue 4, 2014, Pages 320-325

  Tremblay, Cedric S ^a   Curtis, David J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Cell of origin; Clonal evolution; Leukemic stem cell; T cell acute lymphoblastic leukemia

Indexed keywords

CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; HELIX LOOP HELIX PROTEIN; INTERLEUKIN 7; NOTCH1 RECEPTOR; TRANSCRIPTION FACTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; PROTEIN BINDING;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER GROWTH; CANCER RECURRENCE; CELL MATURATION; CLONAL EVOLUTION; GAIN OF FUNCTION MUTATION; HEMATOPOIESIS; LEUKEMOGENESIS; LOSS OF FUNCTION MUTATION; LYMPHATIC LEUKEMIA; PRE T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; STEM CELL NICHE; ANIMAL; CANCER STEM CELL; DISEASE COURSE; GENETIC EPIGENESIS; HUMAN; METABOLISM; PATHOLOGY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CLONAL EVOLUTION; DISEASE PROGRESSION; EPIGENESIS, GENETIC; HUMANS; NEOPLASTIC STEM CELLS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84902274930     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000058     Document Type: Review

References (62)

1. Van Vlierberghe P, Ambesi-Impiombato A, De Keersmaecker K, et al. Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood 2013; 122:74-82.
2. Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, et al. ETV6 mutations in early immature human T cell leukemias. J Exp Med 2011; 208:2571-2579.
3. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481:157-163.
4. De Keersmaecker K, Atak ZK, Li N, et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet 2013; 45:186-190.
5. Tzoneva G, Perez-Garcia A, Carpenter Z, et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med 2013; 19:368-371.
6. Tremblay CS, Hoang T, Hoang T. Early T cell differentiation lessons from T-cell acute lymphoblastic leukemia. Prog Mol Biol Transl Sci 2010; 92:121-156.
7. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008; 322:1377-1380.
8. Corces-Zimmerman MR, Hong WJ, Weissman IL, et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 2014; 111:2548-2553.
9. Shlush LI, Zandi S, Mitchell A, et al. Identification of preleukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506:328-333.
10. Clappier E, Gerby B, Sigaux F, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 2011; 208:653-661.
11. Homminga I, Pieters R, Langerak AW, et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 2011; 19:484-497.
12. Zuurbier L, Gutierrez A, Mullighan CG, et al. Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have nonrearranged T-cell receptors. Haematologica 2014; 99:94-102.
13. Berquam-Vrieze KE, Nannapaneni K, Brett BT, et al. Cell of origin strongly influences genetic selection in a mouse model of T-ALL. Blood 2011; 118:4646-4656.
14. Dik WA, Nadel B, Przybylski GK, et al. Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL. Blood 2007; 110:388-392.
15. Larmonie NS, Dik WA, Meijerink JP, et al. Breakpoint sites disclose the role of the V(D)J recombination machinery in the formation of T-cell receptor (TCR) and non-TCR associated aberrations in T-cell acute lymphoblastic leukemia. Haematologica 2013; 98:1173-1184.
16. Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome: long-term efficacy and genotoxicity. Sci Transl Med 2014; 6:227-33.
17. McCormack MP, Young LF, Vasudevan S, et al. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science 2010; 327:879-883.
18. Tremblay M, Tremblay CS, Herblot S, et al. Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. Genes Dev 2010; 24:1093-1105.
19. Cleveland SM, Smith S, Tripathi R, et al. Lmo2 induces hematopoietic stem cell-like features in T-cell progenitor cells prior to leukemia. Stem Cells 2013; 31:882-894.
20. Smith S, Tripathi R, Goodings C, et al. LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways. PLoS One 2014; 9:e85883.
21. Sanda T, Lawton LN, Barrasa MI, et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell 2012; 22:209-221.
22. Wilson NK, Foster SD, Wang X, et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell 2010; 7:532-544.
23. Mansour MR, Sanda T, Lawton LN, et al. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J Exp Med 2013; 210:1545-1557.
24. Correia NC, Durinck K, Leite AP, et al. Novel TAL1 targets beyond proteincoding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia. Leukemia 2013; 27:1603-1606.
25. Beck D, Thoms JA, Perera D, et al. Genome-wide analysis of transcriptional regulators in human HSPCs reveals a densely interconnected network of coding and noncoding genes. Blood 2013; 122:e12-e22.
26. De Keersmaecker K, Real PJ, Della Gatta G, et al. The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med 2010; 16:1321-1328.
27. Loosveld M, Bonnet M, Gon S, et al. MYC fails to efficiently shape malignant transformation in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 2014; 53:52-66.
28. Grossmann V, Haferlach C, Weissmann S, et al. The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL. Genes Chromosomes Cancer 2013; 52:410-422.
29. Butler JS, Dent SY. The role of chromatin modifiers in normal and malignant hematopoiesis. Blood 2013; 121:3076-3084.
30. Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012; 44:23-31.
31. Jeong M, Sun D, Luo M, et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat Genet 2014; 46:17-23.
32. Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12:599-612.
33. Fried I, Bodner C, Pichler MM, et al. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. Haematologica 2012; 97:246-250.
34. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481:506-510.
35. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150:264-278.
36. Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18:298-301.
37. Simon C, Chagraoui J, Krosl J, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev 2012; 26:651-656.
38. Bracken AP, Dietrich N, Pasini D, et al. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20:1123-1136.
39. Xie H, Xu J, Hsu JH, et al. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell 2014; 14:68-80.
40. Piovan E, Yu J, Tosello V, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 2013; 24:766-776.
41. Rothenberg EV, Moore JE, Yui MA. Launching the T-cell-lineage developmental programme. Nat Rev Immunol 2008; 8:9-21.
42. Barata JT, Cardoso AA, Nadler LM, et al. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by downregulating the cyclin-dependent kinase inhibitor p27(kip1). Blood 2001; 98:1524-1531.
43. Zenatti PP, Ribeiro D, Li W, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011; 43:932-939.
44. Ribeiro D, Melao A, Barata JT. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia. Adv Biol Regul 2013; 53:211-222.
45. Yokoyama K, Yokoyama N, Izawa K, et al. In vivo leukemogenic potential of an interleukin 7 receptor alpha chain mutant in hematopoietic stem and progenitor cells. Blood 2013; 122:4259-4263.
46. Silva A, Laranjeira AB, Martins LR, et al. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res 2011; 71:4780-4789.
47. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306:269-271.
48. Blackburn JS, Liu S, Raiser DM, et al. Notch signaling expands a premalignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. Leukemia 2012; 26:2069-2078.
49. Chiang MY, Xu L, Shestova O, et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 2008; 118:3181-3194.
50. Li X, Gounari F, Protopopov A, et al. Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1. J Exp Med 2008; 205:2851-2861.
51. Chiang MY, Shestova O, Xu L, et al. Divergent effects of supraphysiologic Notch signals on leukemia stem cells and hematopoietic stem cells. Blood 2013; 121:905-917.
52. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006; 20:2096-2109.
53. King B, Trimarchi T, Reavie L, et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 2013; 153:1552-1566.
54. Chan SM, Weng AP, Tibshirani R, et al. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007; 110:278-286.
55. Joshi I, Minter LM, Telfer J, et al. Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood 2009; 113:1689-1698.
56. Sawai CM, Freund J, Oh P, et al. Therapeutic targeting of the cyclin D3:CDK4/ 6 complex in T cell leukemia. Cancer Cell 2012; 22:452-465.
57. Lonetti A, Antunes IL, Chiarini F, et al. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. Leukemia 2013. doi: 10.1038/leu. 2013.369.
58. Roderick JE, Tesell J, Shultz LD, et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 2014; 123:1040-1050.
59. Hagenbeek TJ, Wu X, Choy L, et al. Murine Pten T-ALL requires nonredundant PI3K/mTOR and DLL4/Notch1 signals for maintenance and gammac/TCR signals for thymic exit. Cancer Lett 2014; 346:237-248.
60. Atak ZK, De Keersmaecker K, Gianfelici V, et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes. Plos One 2012; 7:7; e38463.
61. Li Q, Bohin N, Wen T, et al. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature 2013; 504:143-147.
62. Lassen LB, Ballarin-Gonzalez B, Schmitz A, et al. Nras overexpression results in granulocytosis, T-cell expansion and early lethality in mice. PLoS One 2012; 7:e42216.